CGEM Cullinan Oncology Inc

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM) (“Cullinan”) announced today that the company’s Chief Financial Officer, Jeff Trigilio, will present at the upcoming 20th Annual Needham Virtual Healthcare Conference.

Event: Needham Virtual Healthcare Conference

Date: Tuesday, April 13th

Time: 11:45am EDT

Location: Virtual

The presentation will be accessible through the Needham conference portal for registered attendees only. Investors interested in scheduling a meeting with Mr. Trigilio should contact their Needham & Company representative.

About Cullinan Oncology

Cullinan Oncology is a biopharmaceutical company that seeks to drive shareholder returns by focusing on the patient. The Company’s strategy is to build a diversified pipeline of targeted and immuno-oncology therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes. Learn more about Cullinan at .

Contacts:

Investor Relations

Jeff Trigilio

+1 617.410.4650



EN
07/04/2021

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Cullinan Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026, at 1:1...

February 24, 2026 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026...

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET. A webc...

February 18, 2026 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenhei...

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 11:00 a.m. ET....

February 5, 2026 1 EN
Geoffrey Von Der Ahe ... (+2)
  • Geoffrey Von Der Ahe
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
01/08/26 January 8, 2026 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Highlights Anticip...

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch